Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Protocolli di diagnosi e terapia

PDF MeBrain

Convulsioni e stato di male epilettico: schema sinottico per l’intervento in emergenza / urgenza - Aggiornamento 2023

Seizures and status epilepticus: synoptic scheme for emergency / urgency intervention. 2023 Update

Flavio Quarantiello1, Giuseppe Furcolo2
1UOC di Pediatria e Adolescentologia, Ospedale San Pio, Benevento

Dicembre 2023 | DOI: 10.53126/MEBXXVI214

Abstract
The updated revision of the epilepticus status (ES) therapy poster is addressed to all paediatric emergency workers, but not to parents and/or lay people. It does not address the management of neonatal and nonconvulsive seizures. The objective of this poster is to summarize the management and treatment of the child presenting with seizures that may result in progression to ES.
Riassunto
La revisione aggiornata del poster sulla terapia dello stato di male epilettico (SME) è indirizzata a tutti gli operatori dell’Emergenza Pediatrica, ma non ai genitori e/o non addetti ai lavori; non riguarda la gestione delle convulsioni neonatali e delle crisi epilettiche non convulsive.
L’obiettivo di questo poster è sintetizzare la gestione e il trattamento del bambino che presenta una crisi tonico-clonica focale o generalizzata prolungata (premonitrice di SME imminente), SME in atto e SME refrattario secondo la classificazione della International League Against Epilepsy (ILAE) 2017
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Trinka E, Kälviäinen R. 25 years of advances in the definition, classification and treatment of status epilepticus. . Seizure 2017;44:65-73. DOI: 10.1016/j.seizure.2016.11.001.
  2. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus - report of the ILAE Task force on classification of status epilepticus. Epilepsia 2015;56:1515-1523. DOI: 10.1111/epi.13121.
  3. Mitchell C, Chatterton Dickson L, Ramsay A, et al. Epidemiology and outcome of status epilepticus in children: a Scottish population cohort study. Dev Med Child Neurol 2021;63:1075-1084. DOI: 10.1111/dmcn.14900.
  4. Chin RF, Neville BG, Peckham C, Bedford H, Wade A, Scott RC; NLSTEPSS Collaborative Group. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet 2006;368:222-229. DOI: 10.1016/S0140-6736(06)69043-0.
  5. Messahel S, Bracken L, Appleton R. Optimal Management of Status Epilepticus in Children in the Emergency Setting: A Review of Recent Advances. Open Access Emerg Med 2022;14:491-506. DOI: 10.2147/OAEM.S293258.
  6. Shinnar S, Berg AT, Moshe SL, Shinnar R. How long do new-onset seizures in children last? Ann Neurol 2001;5:659-664. DOI: 10.1002/ana.1018.
  7. Zhao Z, Wang H, Wen B, Yang Z, Feng K, Fan J. A comparison of midazolam, lorazepam, and diazepam for the treatment of status epilepticus in children: a network meta-analysis. J Child Neurol 2016;31:1093-107. DOI: 10.1177/0883073816638757.
  8. McTague A, Martland T, Appleton R. Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children. Cochrane Database Syst Rev. 2018 Jan;1(1):CD001905. DOI: 10.1002/14651858.CD001905.pub3.
  9. European Medicines Agency 2022. EMA recommends authorisation of Nasolam (midazolam, nasal spray) in the EU 28/01/2022.
  10. Singh A, Stredny CM, Loddenkemper T. Pharmacotherapy for paediatric convulsive status epilepticus. CNS Drugs 2020;34:47-63. DOI: 10.1007/s40263-019-00690-8.
  11. Abdelgadir I, Hamud A, Kadri A, et al. Levetiracetam for convulsive status epilepticus in childhood: systematic review and meta-analysis. Arch Dis Child. 2020;106:470-6. DOI: 10.1136/archdischild-2020-319573.
  12. Feng Y, Chen Y, Jia Y, et al. Efficacy and safety of levetiracetam versus (fos) phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials. Seizure 2021;91:339-345. DOI: 10.1016/j.seizure.2021.07.012.
  13. Burman RJ, Ackermann S, Shapson-Coe A, Ndondo A, Buys H, Wilmshurst JM. A comparison of parenteral phenobarbital vs. parenteral phenytoin as second-line management for pediatric convulsive status epilepticus in a resource-limited setting. Front Neurol 2019;10:506. DOI: 10.3389/fneur.2019.00506.
  14. Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre open-label, randomised trial. Lancet 2019;393:2125-34. DOI: 10.1016/S0140-6736(19)30724-X.
  15. Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet. 2019;393:2135-45. DOI: 10.1016/S0140-6736(19)30722-6.
  16. Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double blind, response -adaptive, randomised controlled trial. Lancet. 2020;395:1217-24. DOI: 10.1016/S0140-6736(20)30611-5.
  17. Neligan A, Rajakulendran R, Walker MC. Advances in the management of generalized convulsive status epilepticus: what have we learned? Brain 2021;144:1336-41. DOI: 10.1093/brain/awab049.
  18. Lega Italiana Contro l’Epilessia (LICE). La terapia dello stato epilettico, Position Paper. A cura della Commissione Stato Epilettico, 2019.
  19. Van de Voorde P, Turner NM, Djakow J, et al. European Resuscitation Council Guidelines 2021: Paediatric Life Support. Resuscitation 2021;161:327-387. DOI: 10.1016/j.resuscitation.2021.02.015.